Antiangiogenic Agents in Breast Cancer

REFERENCES

• Yancopoulos G. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–248
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Fidler I. J., Ellis L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185–188
   PubMed Web of Science ®Google Scholar
• Carmeliet P., Jain R. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257
   PubMed Web of Science ®Google Scholar
• Brem S. S., Gullino P. M., et al. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195: 880–882
   PubMed Web of Science ®Google Scholar
• Jensen H. M., Chen I., et al. Angiogenesis induced by “normal” human breast tissue: a probable marker for precancer. Science 1982; 218: 293–295
   PubMed Web of Science ®Google Scholar
• Guinbretiere J. M., Le Monique G., et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J. Natl. Cancer Inst. 1994; 86: 635–636
   PubMed Web of Science ®Google Scholar
• Guidi A. J., Schnitt S. J., Fischer L., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997; 80: 1945–1953
   PubMed Web of Science ®Google Scholar
• Weidner N., Semple J. P., Welch W. R., et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Weidner N., Folkman J., Pozza F., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992; 84: 1875–1887
   PubMed Web of Science ®Google Scholar
• Ferrara N., Davis-Smith T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997; 18: 4–25
   PubMed Web of Science ®Google Scholar
• Bouck N., Stellmach V., Hsu S. C. How tumors become angiogenic. Adv. Cancer Res. 1996; 69: 135–174
   PubMed Web of Science ®Google Scholar
• Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2002; 2: 727–739
   PubMed Web of Science ®Google Scholar
• Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995; 55: 4575–4580
   PubMed Web of Science ®Google Scholar
• Dvorak H. P. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002; 20: 4368–4380
   PubMed Web of Science ®Google Scholar
• Brown L. F., Berse B., Jackman R. W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 1995; 26: 86–91
   PubMed Web of Science ®Google Scholar
• Heer K., Kumar H., Read J. R., et al. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res. 2001; 11: 3491–3494
   Google Scholar
• Nishimura R., Nagao K., Miyayama H., et al. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer 2003; 2: 120–128
   Google Scholar
• Toi M., Hoshima S., Takayanagi T., et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 1994; 85: 1045–1049
   PubMedGoogle Scholar
• Linderholm B., Grankvist K., Wilking N., et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 2000; 18: 1423–1431
   PubMed Web of Science ®Google Scholar
• Linderholm B., Tavelin B., Grankvist K., et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. 1998; 16: 3121–3128
   PubMed Web of Science ®Google Scholar
• Foekens J. A., Peters H. A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61: 5407–5414
   PubMed Web of Science ®Google Scholar
• Relf M., Lejune S., Scott P. A., et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet derived endothelial cell growth factor, placenta growth factor, and pleio- trophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997; 57: 963–969
   PubMed Web of Science ®Google Scholar
• Kim K. J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841–844
   PubMed Web of Science ®Google Scholar
• Borgstrom P., Hillan K. J., Sriramarao P., Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996; 56: 4032–4039
   PubMed Web of Science ®Google Scholar
• Asano M., Yukita A., Matsumoto T., et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to vascular endothelial growth factor/vascular permeability factor. Cancer Res. 1995; 55: 5296–5301
   PubMed Web of Science ®Google Scholar
• Yuan F., Chen Y., Dellian M., et al. Time-dependent vascular regression and vascular permeability changes in established xenografts induced by anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 1996; 93: 14,765–14,770
   Google Scholar
• Presta L. G., Chen H., O'Connor S. J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57: 4593–4599
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Johnson D. H., Fehrenbacher L., Novotny W. F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2004; 22: 2184–2191
   PubMed Web of Science ®Google Scholar
• Yang J., Haworth L., Sherry R. M., et al. Randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cell cancer. N. Engl. J. Med. 2003; 349: 427–434
   PubMed Web of Science ®Google Scholar
• Cobleigh M., Langmuir V., Sledge G., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem. Oncol. 2003; 5: 117–124, (suppl 16)
   Web of Science ®Google Scholar
• Gasparini G., Longo R., Fanelli M., Teicher B. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol. 2005; 23: 1295–1311
   PubMed Web of Science ®Google Scholar
• Kakeji Y., Teicher B. A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15: 39–48
   PubMed Web of Science ®Google Scholar
• Jain R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62
   PubMed Web of Science ®Google Scholar
• Miller K. D., Chap L., Holmes F., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005; 23: 792–799
   PubMed Web of Science ®Google Scholar
• Miller K. D., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94, www.sabcs.org (suppl 1) (abstract 3)
   Web of Science ®Google Scholar
• Miller K. D., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Data presented at San Antonio Breast Cancer Symposium—obtained through personal correspondence. 2005
   Google Scholar
• Overmoyer B., Silverman P., Leeming R., et al. Phase II trial of neodjeuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 2004; 23, www.asco.org(abstract 727)
   Google Scholar
• Ramaswamy B., Shapiro C. L. Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin Breast Cancer 2003; 4: 292–294
   PubMedGoogle Scholar
• Burstein H., Parker L., Savoie J., et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002; 76: S115, (abstract 446)
   Web of Science ®Google Scholar
• Traina T. A., Dickler M. N., Caravelli J. F., et al. A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer. Breast Cancer Res. Treat 2005; 94, (suppl 1), (abstract 2030)
   Web of Science ®Google Scholar
• Bonthala Wedam S., Low J. A., Yang S. X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 2005; 24: 769–776
   Web of Science ®Google Scholar
• Koukourakis M. I., Giatromanolaki A., O'Byrne K. J., et al. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and thymidine phosphorylase angiogenic activity in non-small cell lung cancer. Clin. Exp. Metastasis 1999; 17: 545–554
   PubMed Web of Science ®Google Scholar
• Petit A. M., Rak J., Hung M. C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997; 151: 1523–1530
   PubMed Web of Science ®Google Scholar
• Blackwell K. L., Dewhirst M. W., Liotcheva V., et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin. Cancer Res. 2004; 10: 4083–4088, (12 pt 1)
   PubMed Web of Science ®Google Scholar
• Konecny G. E., Meng Y. G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res. 2004; 10: 1706–1716
   PubMed Web of Science ®Google Scholar
• Pegram M. D., Reese D. M. Combined biologic therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin. Oncol. 2002; 3: 29–37, (suppl ll)
   Google Scholar
• Pegram M. D., Yeon C., Ku N. C., et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat 2004; 88, www.sabcs.org(suppl 1), (abstract 3039)
   Web of Science ®Google Scholar
• Maity A., Pore N., Lee J., et al. Epidermal growth factor receptor transcriptionally up- regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res. 2000; 60: 5879–5886
   PubMed Web of Science ®Google Scholar
• Sini P., Wyder L., Schnell C., et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by erbBl blockade. Clin. Cancer Res. 2005; 11: 4521–4532
   PubMed Web of Science ®Google Scholar
• Heffelfinger S. C., Yan M., Gear R. B., et al. Inhibition of VEFR2 prevents DMBA-induced mammary tumor formation. Lab. Invest. 2004; 84: 989–998
   PubMed Web of Science ®Google Scholar
• Miller K., Trigo J., Stone A., et al. A phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer (MBC). Breast Cancer Res. Treat 2004; 88: S240, (abstract 6060)
   Web of Science ®Google Scholar
• Rugo H. S., Didder M. N., Scott J. H., et al. Circulating endothelial cell (CEC) and tumor cell (CTC) analysis in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC). Breast Cancer Res. Treat 2004; 88, (suppl 1), (abstract 3088)
   Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2001; 2: 733–740
   PubMed Web of Science ®Google Scholar
• Miller K. D., Sweeney C. J., Sledge G. W. Redefining the target: chemotherapeutics as anti-angiogenics. J. Clin. Oncol. 2001; 19: 1195–1206
   PubMed Web of Science ®Google Scholar
• Hanahan D., Bergers G., Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–1047
   PubMed Web of Science ®Google Scholar
• Gately S., Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001; 7: 427–436
   PubMed Web of Science ®Google Scholar
• Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003; 63: 4342–4346
   PubMed Web of Science ®Google Scholar
• Yap R., Veliceasa D., Emmenegger U., et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation to antiangiogenic strategy. Clin. Cancer Res. 2005; 11: 6678–6685
   PubMed Web of Science ®Google Scholar
• Munoz R., Shaked Y., Bertolinin F., et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005; 14: 466–479
   PubMed Web of Science ®Google Scholar
• Colleoni M., Rocca A., Sandri T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Annal. Oncol. 2002; 13: 73–80
   PubMed Web of Science ®Google Scholar
• Burstein H. J., Spigel D., Kindsvogel K., et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res. Treat 2005; 94, www.sabcs.org(suppl 1), (abstract 4)
   Web of Science ®Google Scholar
• Abrams T. J., Murray L. J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003; 2: 1011–1021
   PubMed Web of Science ®Google Scholar
• Miller K. D., Burstein H. J., Elias A. D., et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). Breast Cancer Res Treat 2005; 94, (suppl 1), (abstract 1066)
   Web of Science ®Google Scholar
• Hidalgo M., Eckhardt S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. (Bethesda) 2001; 93: 178–193
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Bernardo P., Gradishar W. J., et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first line chemotherapy: an Eastern Cooperative Oncology Group Trial (E2196). Proc. Am. Soc. Clin. Oncol. 2002; 21: 44a
   Google Scholar
• Moore M., Hamm J., Eisenberg P., et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 240a
   Google Scholar
• Klauber N., Parangi S., Flynn E. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997; 57: 81–86
   PubMed Web of Science ®Google Scholar
• Han G. Z., Liu Z. J., Shimoi K., et al. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 2005; 65: 387–393
   PubMed Web of Science ®Google Scholar
• Sledge G., Miller K., Haney L., et al. A phase I study of 2-methoxyestradiol (2ME2) in patients with refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: IIIa, (abstract 441)
   Google Scholar
• Miller K., Murry D., Curry E., et al. A phase I study of 2-methoxyestradiol (2ME2) plus docetaxel in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: IIa, (abstract 442)
   Google Scholar
• Longo R., Sarmiento R., Fanelli M., et al. Anti-angiogenic therapy: rationale, challenges, and clinical studies. Angiogenesis 2002; 5: 237–256
   PubMedGoogle Scholar
• Pearlman J. D., Laham R. J., Post M., et al. Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr. Pharm. Des. 2002; 8: 1467–1496
   PubMed Web of Science ®Google Scholar
• Costouros N. G., Diehn F. E., Libutti S. K. Molecular imaging of tumor angiogenesis. J. Cell Biochem. 2002; 39: 72–78, (suppl)
   Google Scholar
• Gasparini G., Gion M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper end-points. Cancer J 2000; 6: 117–131
   PubMed Web of Science ®Google Scholar
• Lissoni P., Fugamalli E., Malugani F., et al. Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer. Int. J. Biol. Markers 2000; 15: 308–311
   PubMed Web of Science ®Google Scholar
• Bergsland E., Dickler M. Maximizing the potential of bevacizumab in cancer treatment. The Oncologist 2002; 9: 36–42, (suppl)
   Web of Science ®Google Scholar
• Hillan K. J., Koeppen H. K.W., Tobin P., et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2003; 22: 191
   Google Scholar
• Schneider B. P., Miller K. D. Angiogenesis of breast cancer. J. Clin. Oncol. 2005; 23: 1782–1790
   PubMed Web of Science ®Google Scholar
• Karp J. E., Gojo I., Pili R., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 2004; 10: 3577–3585
   PubMed Web of Science ®Google Scholar
• D'Adamo D. R., Anderson S. E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 2005; 23: 7135–7142
   PubMed Web of Science ®Google Scholar